Загрузка...
Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells
BACKGROUND: Triple-negative breast cancer (TNBC) has aggressive progression with poor prognosis and ineffective treatments. Selumetinib is an allosteric, ATP-noncompetitive inhibitor of MEK1/2, which has benn known as effective antineoplastic drugs for several malignant tumors. We hypothesized that...
Сохранить в:
| Опубликовано в: : | BMC Cancer |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5073736/ https://ncbi.nlm.nih.gov/pubmed/27769200 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2773-4 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|